Sildenafil orodispersible film in the treatment of erectile dysfunction after radical prostatectomy: A single‐centre open‐label uncontrolled trial

Andrologia ◽  
2020 ◽  
Vol 52 (9) ◽  
Author(s):  
Carlo Pavone ◽  
Alberto Abrate ◽  
Sonia Agiato ◽  
Sandro Billeci ◽  
Gabriele Tulone ◽  
...  
2014 ◽  
Vol 33 (3) ◽  
pp. 301-307 ◽  
Author(s):  
Wael Y. Khoder ◽  
Raphaela Waidelich ◽  
Michael Seitz ◽  
Armin J. Becker ◽  
Alexander Buchner ◽  
...  

2020 ◽  
Vol 72 (5) ◽  
Author(s):  
Michele Marchioni ◽  
Piergustavo De Francesco ◽  
Roberto Castellucci ◽  
Rocco Papalia ◽  
Selçuk Sarikaya ◽  
...  

2015 ◽  
Vol 21 (11) ◽  
pp. 1440-1454 ◽  
Author(s):  
Serap Gur ◽  
Suresh C. Sikka ◽  
Philip Kadowitz ◽  
Jonathan Silberstein ◽  
Wayne Hellstrom

2020 ◽  
Vol 16 (27) ◽  
pp. 2035-2044
Author(s):  
Charlien Berghen ◽  
Steven Joniau ◽  
Annouschka Laenen ◽  
Gaetan Devos ◽  
Kato Rans ◽  
...  

Radical prostatectomy is a well-established treatment option in the management of localized and locally advanced prostate cancer. An extended lymphadenectomy is performed in case of substantial risk for lymph node involvement. When biochemical recurrence (BCR) occurs, salvage radiotherapy (SRT) is performed. The benefit in terms of BCR-free survival (FS) and metastasis-FS by adding 6 months of androgen deprivation therapy (ADT) compared with SRT only has already been established. Retrospective evidence suggests that a longer schedule of ADT may be more beneficial compared with 6 months. This multicenter open-label randomized trial will include patients who need SRT after experiencing BCR post-radical prostatectomy with lymphadenectomy and pN0-status. Patients will be randomized for ADT duration (6 vs 24 months). Primary end point is distant metastasis-FS. Clinical Trial Registration: NCT04242017 ( ClinicalTrials.gov )


Sign in / Sign up

Export Citation Format

Share Document